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Introduction {#sec1}
============

Histone variants replace core histones to perform a variety of specialized functions ([@bib62]) and, as canonical histones, are prone to posttranslational modifications (PTMs). H2A.Z is an evolutionarily conserved histone variant of the canonical histone H2A, which shares ∼60% identity in amino acid sequence (reviewed in [@bib71]). H2A.Z has been implicated in many diverse and potentially opposing functions, including regulation of gene transcription, where H2A.Z has been associated with active, poised, or inactive gene expression. The contrasting roles of H2A.Z are associated with different PTMs, including lysine acetylation, monoubiquitination, and methylation (reviewed in [@bib52]) ([@bib6]).

Acetylated H2A.Z (H2A.Zac) is associated with active transcription ([@bib63], [@bib64], [@bib40], [@bib65]) and promotes nucleosome destabilization and an open chromatin conformation ([@bib25]). In mammals, lysines 4, 7, and 11 (K4, K7, K11) in the H2A.Z N-terminal tail are the most frequently acetylated residues ([@bib25]). Genome-wide studies based on H2A.Zac ChIP on-chip or ChIP-seq in different cell types and organisms have revealed that the acetylated H2A.Z forms are primarily restricted to genomic regulatory regions, such as promoters and enhancers ([@bib63], [@bib66], [@bib24], [@bib67], [@bib40], [@bib54], [@bib65]). We and others have shown that H2A.Zac is associated with aberrant gene expression in prostate ([@bib68], [@bib65]) and breast cancer ([@bib2], [@bib11], [@bib12]). Recently, we found that increased H2A.Zac levels correlate with poor prognosis in prostate cancer patients and demonstrated a pro-oncogenic role for H2A.Zac through the ectopic activation of cancer-related enhancers ([@bib54]). Collectively, these data suggest that inhibition of H2A.Z acetylation may be a therapeutic strategy for treating prostate cancer. However, the molecular mechanisms and key players responsible for the acetylation of H2A.Z are not fully understood.

Histone lysine acetylation is catalyzed by lysine acetyltransferases (KATs). In mammalian cells, nine nuclear KATs have been identified, from which three---Tip60, CREB binding protein (CBP), and E1A binding protein p300 (p300) ---can acetylate canonical histones ([@bib27], [@bib29]). In the budding yeast *Saccharomyces cerevisiae*, the lysine acetyltransferase NuA4, considered the orthologue of Tip60 ([@bib16]), is reported to acetylate Htz1, the yeast orthologue of H2A.Z ([@bib1], [@bib31], [@bib40]). Indeed, studies in mammalian cells have suggested a link between H2A.Zac and the Tip60 complex in locus-specific experiments ([@bib11], [@bib12], [@bib20]) and by immunoprecipitation of the Tip60 complex followed by KAT assays with recombinant H2A.Z ([@bib26]). However, other studies showed that H2A.Zac was independent of Tip60 inhibition at locus-specific sites ([@bib2], [@bib42]) and in the context of DNA repair ([@bib51]), suggesting that other KATs may also be responsible for H2A.Zac.

CBP and p300 (also known as CREBBP or KAT3A and EP300 or KAT3B, respectively) are highly homologous proteins that comprise a unique KAT family and are often referred to interchangeably. p300/CBP is a transcriptional co-activator and catalyses lysine 27 acetylation of histone H3 (H3K27ac) at promoters and enhancers ([@bib10], [@bib23]). p300/CBP is a multifunctional protein that acts as both a "writer" and a "reader" of lysine acetylation through its KAT domain and bromodomain (BD), respectively ([@bib13], [@bib61]). p300/CBP is a promiscuous KAT that can acetylate all four canonical histones ([@bib59]). However, p300/CBP\'s ability to acetylate and/or interact with H2A.Z has not been critically evaluated.

In this study, we have interrogated two of the most likely KAT candidates for the acetylation of H2A.Zac: Tip60 and p300/CBP. Here, we provide *in vitro* evidence, with peptide and recombinant nucleosome substrates, that Tip60 does not efficiently acetylate H2A.Z. In contrast, we demonstrate that p300 can acetylate H2A.Z at multiple lysine residues, both *in vitro* and in human cells, and H2A.Zac is enhanced by p300 BD-mediated H4ac reader activity. In support of this mechanism, we find a high degree of genomic overlap between H2A.Zac and H4ac at active regulatory regions, preferentially at active promoters. However, at enhancers, we find that H2A.Zac and H4ac nucleosome occupancy is differentially associated with distinct chromatin features and the transcriptional activity of the genomic region. Overall, our findings suggest that in addition to Tip60, p300/CBP is also required for H2A.Z acetylation, providing new insights for the modulation of H2A.Zac pro-oncogenic activity in prostate cancer.

Results {#sec2}
=======

p300 Acetylates H2A.Z *In Vitro* {#sec2.1}
--------------------------------

To test whether our putative KAT candidates acetylated H2A.Z, we performed *in vitro* lysine acetyltransferase assays with recombinant Tip60 and p300 ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). As substrates, we used biotinylated peptides corresponding to the first 19 amino acids of H2A.Z ([Figure 1](#fig1){ref-type="fig"}A) and observed acetylation rates by measuring radioactive acetyl group incorporation ([Figure 1](#fig1){ref-type="fig"}B). As a negative control, we used an H2A.Z peptide containing the most commonly acetylated lysines (K4, K7, and K11) ([@bib24], [@bib25]). For positive controls, known substrates for each KAT were used, including an H4 N-terminal peptide for Tip60 ([@bib69]) and an H3 peptide flanking H3K27 for p300 ([@bib70]). Recombinant Tip60 rapidly acetylated the positive control H4 peptide. However, H2A.Z only showed a slight increase in acetylation signal compared with the negative control H2A.ZK4acK7acK11ac ([Figure 1](#fig1){ref-type="fig"}B, upper panel and [Figure S1](#mmc1){ref-type="supplementary-material"}C). These data suggest that H2A.Z peptides are not optimal substrates for recombinant Tip60. In contrast, recombinant p300 (catalytic domain plus BD) ([Figure S1](#mmc1){ref-type="supplementary-material"}A), which shares 82% of protein domain identity with CBP, acetylated H2A.Z peptides at a similar rate to its most appreciated histone substrate, H3K27 ([Figure 1](#fig1){ref-type="fig"}B, bottom panel). We confirmed this activity with full-length recombinant p300 ([Figure S1](#mmc1){ref-type="supplementary-material"}D). p300 activity toward peptide substrates of H2A.Z isoform 2 ([@bib18]) was similar to isoform 1 (referred herein as H2A.Z) ([Figures S1](#mmc1){ref-type="supplementary-material"}E and S1F).Figure 1H2A.Z Is a Substrate for p300 *In Vitro* Assays(A) H2A.Z-1 N-terminal amino acid sequence for the peptides used in panel (B). All lysines that can be acetylated are shown in red.(B) In-solution H^3^-Acetyl-CoA (AcCoA) assays measuring Tip60 (top) and p300 (bottom) activity as a function of time on the following histone peptide substrates: un-acetylated H2A.Z (peptide spans from amino acid 1--19, H2A.Z-1 ~(1-19)~) and the tri-acetylated H2AZ at lysines 4, 7, and 11 (1--19) (H2A.Z-1 ~(1-19)~K4acK7acK11ac) were used for both Tip60 and p300 assays. As controls we used H4 (1--23) and acetylated H4 at lysines 5, 8, 12, and 16 (1--23) (H4~(1-23)~K5acK8acK12acK16ac) for Tip60 and H3 (15--34) and acetylated H3 at lysine 27 peptides (15--34) (H3~(15-34)~K27ac) for p300. Data points are presented as mean count per minute (cpm). Error bars represent the standard deviation (SD) from two measurements.(C) Coomassie staining (left) and H^3^ fluorography (right) of recombinant canonical nucleosomes (canonical nuc) and homotypic H2A.Z-1 nucleosomes (H2A.Z-1 nuc) incubated with Tip60 in the presence or absence of H^3^-AcCoA for 12 h. White bands in the autoradiography are the overlayed molecular weight markers shown in the Coomassie staining. Representative image of two replicates.(D) H^3^ fluorography (top) and Coomassie staining (bottom) of recombinant canonical nucleosomes (canonical nuc) and homotypic H2A.Z-1 and H2A.Z-2 nucleosomes (H2A.Z-1/H2A.Z-2 nuc) incubated with p300 in the presence or absence of H^3^-AcCoA for 30 min. Representative image of two replicates.(E) In-solution H^3^-AcCoA KAT assays measuring p300 activity as a function of time on nucleosome substrates, as indicated. Data points are presented as mean count per minute (cpm). Error bars represent the SD from two measurements.(F) Percentage of area under the mass spectrometry (MS) peak of unacetylated, one acetylated lysine (mono-ac), two acetylated lysines (di-ac), three acetylated lysines (tri-ac), or four acetylated lysines (tetra-ac) from H2A.Z peptides at increasing p300 incubation time points, 0, 4, 8, 16, 32, and 64 min (raw data are displayed in [Figure S2](#mmc1){ref-type="supplementary-material"}.). Data are represented as mean −/+ SD of two independent replicates.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

H2A.Z-containing nucleosomes have slightly different biophysical properties than those containing canonical H2A, including an extended acidic path on the nucleosome surface ([@bib53]), which may affect the interactions with KAT domains. To confirm our peptide results on more physiologically relevant substrates, we performed *in vitro* KAT assays using recombinant mononucleosome substrates ([Figures 1](#fig1){ref-type="fig"}C and 1D). Reactions were separated by gel electrophoresis and incorporation of tritiated acetyl groups was detected using autoradiography, allowing deconvolution of which histones were acetylated. Consistent with our peptide results, recombinant Tip60 acetylated H4 in both canonical and H2A.Z-1-containing nucleosomes ([Figure 1](#fig1){ref-type="fig"}C); however, no acetylation of H2A.Z was detected. Moreover, we found Tip60 autoacetylation, which positively regulates Tip60 catalytic activity ([@bib60]), suggesting that the recombinant Tip60 is functionally active. In contrast, p300 acetylated all histones in the canonical nucleosomes after 30 min of incubation ([Figure 1](#fig1){ref-type="fig"}D), as previously reported ([@bib45], [@bib50]). Notably, p300 also acetylated all histones in the H2A.Z-1- and H2A.Z-2-containing nucleosomes, including both H2A.Z isoforms ([Figure 1](#fig1){ref-type="fig"}D). Canonical nucleosomes were a slightly better substrate than variant-containing nucleosomes, but no differences were found in the acetylation rates between nucleosomes containing H2A.Z-1 and H2A.Z-2 isoforms ([Figure 1](#fig1){ref-type="fig"}E).

Mass spectrometry data from human cells have shown that H2A.Zac is found most commonly as a tri-acetylated form, with lysines 4, 7, and 11 (K4, K7 and K11) carrying acetyl groups ([@bib24], [@bib25]). To determine whether p300 acetylates these residues, we used mass spectrometry to map acetylation sites on H2A.Z N-terminal peptide after reaction with p300 ([Figures 1](#fig1){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}A). By four minutes, 90% of all peptides were acetylated, and unacetylated peptides were not detectable in the subsequent time points. Mono-acetylated (mono-ac) peptides were only present after 4, 8, or 16 min, and the proportion decreased by half over the time course (63.6%, 36.9%, and 17.8%, respectively). In contrast, tetra-acetylated peptides were detected (14.4% and 21.1%) at the longest time points (32 and 64 min). Tandem MS analysis showed that all lysines on the N-terminus of H2A.Z (K4, K7, K11, K13, and K15) could be acetylated by p300, but K4 and K7 were preferred ([Figure S2](#mmc1){ref-type="supplementary-material"}B).

In summary, we provide biochemical evidence that the lysine acetyltransferase Tip60 alone is not sufficient to acetylate H2A.Z. In contrast, we show that p300 on its own rapidly acetylates both H2A.Z peptides and H2A.Z-containing nucleosomes at multiple N-terminal lysines.

Inhibition of p300 and Tip60 Decreases H2A.Zac {#sec2.2}
----------------------------------------------

To determine whether p300 and Tip60 acetylate H2A.Z in cells, we used A-485, a recently developed and highly selective and potent inhibitor for p300/CBP KAT domains ([@bib35]) ([Figure 2](#fig2){ref-type="fig"}A), as well as genetic inhibition of Tip60, p300, and CBP by siRNA in two human cancer cell lines (LNCaP and HCT116) ([Figures 2](#fig2){ref-type="fig"}B and 2C). We isolated chromatin fractions from all conditions and performed Western blot analysis. To test changes in H2A.Z acetylation, we used three antibodies against different H2A.Z acetylation forms: H2A.Ztri-ac (K4, K7 and K11), H2A.ZK4ac, and H2A.ZK7ac. We characterized the antibody substrate affinity by peptide microarray, as previously described ([@bib48]). We found that H2A.Ztri-ac specifically recognizes the tri-acetylated form of H2A.Z; H2A.ZK4ac binds to substrates that contain H2A.ZK4ac but does not distinguish between degrees of acetylation, whereas H2A.ZK7ac binds exclusively to mono-acetylated H2A.Z at K7 ([Figure S3](#mmc1){ref-type="supplementary-material"}).Figure 2Inhibition of Tip60 and p300 Decrease H2A.Z Acetylation in Cancer Cell Lines(A) Western blot analysis of chromatin purified extracts from LNCaP and HCT116 cells treated with A-485 for 24 h at increasing concentrations (0.08, 0.4, 2, and 10 μM). The compound A-486, an inactive analog of A-485, was also used as negative control. The figure shows a representative image of two biological replicates (top) and densitometry quantification (bottom). Densitometry quantification of histone acetylation abundance is shown at the bottom, and it is represented as the relative amount to DMSO control in logarithmic scale. H2A.Z acetylation forms were normalized to total H2A.Z; H3K27ac and H4ac were normalized to H4. Data are represented as mean and SD (n = 2). Student\'s t-test was performed to compare each condition to DMSO. \*p value\<0.05, \*\*p value\<0.01, \*\*\*p value\<0.001.(B) Quantification of the knockdown (KD) levels of the siRNA experiments by mRNA expression (left panel) and protein abundance of TIP60 (right panel). Cells were transfected with a pool of four siRNAs for Tip60 and CBP and three siRNAs for p300 (See [Table S3](#mmc1){ref-type="supplementary-material"} for siRNA sequences). The pools were then combined accordingly for the double p300/CBP KD and triple p300/CBP/Tip60 KD. mRNA expression of Tip60, p300, and CBP was measured by real-time qPCR in cells transfected with Tip60, p300, and CBP siRNAs (left). mRNA levels of all conditions were calculated relative to untargeted siRNA control (scramble). Data are represented as mean and SD (n = 2), and Student\'s t-test was performed to compare each condition to scramble. Densitometry quantification of each Tip60 band was normalized to the loading control H4 and relative to scramble, and it is represented as logarithmic scale. The mean relative abundance of each band and SD was plotted and Student\'s t-test was performed to compare each condition to scramble. \*p value\<0.05, \*\*p value\<0.01, \*\*\*p value\<0.001. Find list of siRNA and primer sequences in [Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}, respectively.(C) Western blot analysis of the chromatin fractions from LNCaP cells transfected with the scramble control (Scrble) Tip60 siRNA (siTIP60), p300, and CBP siRNAs (sip300/CBP) or p300, CBP, and Tip60 siRNAs (sip300/CBP/TIP60). The figure shows a representative image of at least two biological replicates (top) and densitometry quantification (bottom). Histone acetylation abundance was measured by densitometry and calculated relative to the scramble control. Data are represented as mean and SD (n = 2 or more). The graph is shown in a logarithmic scale, and Student\'s t-test was performed to compare each condition to scramble. \*p value\<0.05, \*\*p value\<0.01, \*\*\*p value\<0.001.(D) Weinert et al.'s acetylome mass spectrometry data after CBP/p300 perturbations, including double knockout of p300 and CBP genes (KO, dark blue) and chemical inhibition with A-485 (A-485, yellow) and compound-R (Cmpd-R, light blue) in mouse embryonic fibroblasts cells. Kasumi-1 cells, a human acute myeloid leukemia cell line, were treated with compound-R (red). *L*og2 SILAC normalized ratios for each detectable acetylation site of H2A.Z-1 and H2A.Z-2 isoforms were plotted. SILAC normalized ratios were calculated as explained in [@bib59]. The peptides containing K4ac are identical between isoforms, and therefore, they were analyzed as one. Error bars represent standard error of three independent replicates when available.See also [Figure S3](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"}, [S3](#mmc1){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}.

Using these antibodies, we found that cells treated with A-485 had a strong and consistent dose-dependent reduction of the positive control H3K27ac between cell lines, whereas the less specific substrate, H4tetraAc, did not show a clear reduction ([Figure 2](#fig2){ref-type="fig"}A). Signal from the H2A.Ztri-ac antibody did not show a significant reduction in either of the cell lines, whereas H2A.ZK4ac and H2A.ZK7ac showed a clear dose-dependent decrease. At 10 μM concentration of A-485, the mono-acetylated H2A.Z antibodies showed an average reduction of 67% and 92% in LNCaP and HCT116 cells, respectively. No clear differences were detected between the reduction of H2A.ZK4ac and H2A.ZK7ac. These data suggest that inhibition of p300/CBP by A-485 preferentially reduces H2A.ZK4ac and H2A.ZK7ac mono-acetylated forms.

There are currently no selective Tip60 inhibitors commercially available. Therefore, we performed siRNA knockdown (KD) experiments to investigate the effects on H2A.Zac ([Figures 2](#fig2){ref-type="fig"}B and 2C). Tip60 mRNA levels were reduced by 87% and protein abundance by 80% following Tip60 KD ([Figures 2](#fig2){ref-type="fig"}B and 2C). H2A.Zac was significantly reduced after Tip60 KD, 58% for the triAc, 45% for K4ac, and 79% for K7ac ([Figure 2](#fig2){ref-type="fig"}C), as previously reported in Tip60 conditional knockout experiments ([@bib36]). We found that the tetra-acetylated form of H4 was reduced by 64%, in line with our cell-free assays. We also performed siRNA experiments for the double p300/CBP KD and a triple p300/CBP/Tip60 KD. Even though the mRNA levels of p300 and CBP in the double KD were moderately decreased (∼50% and 32%, respectively, [Figure 2](#fig2){ref-type="fig"}B), the positive control H3K27ac was reduced by 92% ([Figure 2](#fig2){ref-type="fig"}C), suggesting the HAT inhibition was enough to detect changes in the histone acetylation profile. Interestingly, Tip60 mRNA levels increased by two-fold after p300/CBP KD but this did not translate to a significant change of Tip60 protein level ([Figure 2](#fig2){ref-type="fig"}B). The double p300/CBP KD reduced all H2A.Zac forms to a similar ratio as the Tip60 KD ([Figure 2](#fig2){ref-type="fig"}C). However, the triple KD of CBP, p300 and Tip60 showed a greater reduction of H2A.Z acetylation in comparison to the single Tip60 or p300/CBP KDs ([Figures 2](#fig2){ref-type="fig"}B and 2C). Interestingly, K7 acetylation was the most reduced in all KD combinations, with 97% reduction in the triple KD.

A recent resource paper mapped the p300 acetylome in mammals using quantitative mass spectrometry after genetic or chemical modulation of p300 activity ([@bib59]). We analyzed this H2A.Z acetylation data and confirmed our *in vitro* and in-cell results ([Figure 2](#fig2){ref-type="fig"}D). Consistently, H2A.Z acetylation at lysines K4, K7, K11, and K13 was reduced after chemical inhibition of p300 KAT activity in both MEFs and Kasumi-1 cell lines ([Figure 2](#fig2){ref-type="fig"}D). The greatest effect was observed in the p300/CBP double knockout. Taken together, these data strongly support the conclusion that p300/CBP is a major KAT for H2A.Z in cells. We found that although Tip60 can modulate acetylation levels of H2A.Zac, it is not the sole KAT for H2A.Z and that p300/CBP is also essential for the acetylation of H2A.Z ([Figure 6](#fig6){ref-type="fig"}A).

Interaction of p300 BD with H4ac Promotes p300-mediated H2A.Z Acetylation *In Vitro* {#sec2.3}
------------------------------------------------------------------------------------

Previous studies have shown that p300 BD binds H4ac, thereby acting as a reader of histone acetylation ([@bib14], [@bib43]). Interestingly, there is high sequence homology between H4 and H2A.Z at their N-termini ([Figure S4](#mmc1){ref-type="supplementary-material"}A), where the spacing of the lysines follow the same KAc(X)~2--3~KAc pattern, in which X represents any amino acid, which is reported to have the strongest p300 BD binding ([@bib14]). We questioned whether the p300 BD was also capable of reading H2A.Zac. Using histone peptide arrays printed with approximately 260 uniquely modified histone peptides ([@bib8]), including major single and combinatorial acetylations on all four core histones and the variant H2A.Z (see [Table S1](#mmc2){ref-type="supplementary-material"}), we revealed that p300 BD binds exclusively to H4-acetylated peptides ([Figures 3](#fig3){ref-type="fig"}A and [S4](#mmc1){ref-type="supplementary-material"}B). No binding was measured for acetylated H2A.Z or any other acetylated histone peptide in the library.Figure 3Bromodomain Binding to H4-Acetylated Tail Enhances H2A.Z Acetylation(A) Heatmap showing p300 BD binding preference for H2A.Z and H4 peptides from histone peptide microarray analysis. Scalebar shows the color key to the relative intensity, normalized to the peptide with the highest raw signal (H4K5acK8acK12acK16ac). Data are represented as mean normalized signal (n = 6). Array 1 was used for this experiment. The complete list of peptides included in the histone peptide microarray is in [Table S1](#mmc2){ref-type="supplementary-material"}.(B) H^3^ fluorography (top) and Coomassie staining (bottom) of H2A canonical nucleosomes (canonical nuc) or H4K5acK8acK12acK16ac pre-marked canonical nucleosomes (H4ac-canonical nuc) incubated with p300 over time (0, 2, 4, 8, and 16 min). Representative image of two experiments. The right plot shows the quantification of the acetylated band density corresponding to H2A/H2B/H3 in the canonical nucleosome and H4ac-canonical nucleosome over time.(C) H^3^ fluorography (top) and Coomassie staining (bottom) of H2A.Z-1 nucleosomes incubated with p300 over time (0, 2, 4, 8, 16, 32, and 64 min). The right plot shows the density quantificatification of H2B/H3, H2A.Z, and H4 acetylated bands over time.(D) Heatmap showing p300 BD binding preference for H2A.Z and H4 peptides in the presence or absence of CBP30 inhibitor from histone peptide microarray analysis. DMSO was used as vehicle control. Scalebar shows the color key to the relative intensity, normalized to the IgG positive control of each array. Data are represented as mean normalized signal (n = 6). Array 1 was used for this experiment. The complete list of peptides included in the histone peptide microarray is in [Table S1](#mmc2){ref-type="supplementary-material"}.(E) H^3^ fluorography (top) and Coomassie staining (bottom) of canonical, H2A.Z-1 and H4K5acK8acK12acK16ac modified canonical nucleosomes incubated with p300 in the presence of CBP30 or DMSO as indicated.(F) Western blot analysis of HCT116 cells treated with CBP30 for 24 h at increasing concentrations (1, 2.5, 5, and 10 μM). Representative image of at least two biological replicates (top) and densitometry quantification represented in logarithmic scale (bottom). Protein abundance was calculated relative to DMSO control, and data are represented as mean and SD (n = 2). Student\'s t-test was performed to compare each condition to DMSO. \*p value\<0.05, \*\*p value\<0.01, \*\*\*p value\<0.001.See also [Figure S4](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}.

A feedforward mechanism of p300-dependent H3K27 acetylation through BD recruitment to H4ac has been previously proposed ([@bib43]). Indeed, in our *in vitro* KAT assays, the rate of p300 acetylation on nucleosomes pre-installed with H4ac was faster than unmodified nucleosomes ([Figure 3](#fig3){ref-type="fig"}B). Thus, we hypothesized that the p300 BD interaction with H4ac may also enhance H2A.Z acetylation. To test this hypothesis, we first performed a time course radioactive KAT assay with recombinant p300 and H2A.Z-containing nucleosome substrates ([Figure 3](#fig3){ref-type="fig"}C). As expected, we observed time-dependent acetylation on all nucleosomal histones. Notably, H2A.Z acetylation trailed H4 acetylation in this time course.

We next used the p300 BD inhibitor, CBP30 ([@bib7], [@bib21]), to further question whether p300 BD activity impacts H2A.Z acetylation. Using the same peptide array approach, we validated that CBP30 completely blocks the p300 BD from binding to H4-acetylated peptides ([Figures 3](#fig3){ref-type="fig"}D, [S4](#mmc1){ref-type="supplementary-material"}C, and S4D). We performed *in vitro* KAT assays in the presence and absence of CBP30 using recombinant canonical, H2A.Z-containing, and H4ac-containing nucleosomes. Inhibition of the p300 BD resulted in decreased acetylation of all histones, including histone H2A.Z ([Figure 3](#fig3){ref-type="fig"}E). To further validate that BD recruitment enhances p300-mediated H2A.Z acetylation, we treated HCT116 cells with CBP30 for 24 h using a concentration range (1--10uM), recommended by [@bib7] ([Figure 3](#fig3){ref-type="fig"}F). We observed a reduction in H3K27ac levels, as previously reported ([@bib46]). Notably, there was also a decrease in H2A.Zac levels, where H2A.ZK7ac showed a striking reduction of up to 90%. Taken together, these data suggest that acetylation of H2A.Z by p300 is enhanced upon recruitment to H4-acetylated nucleosomes via the p300 BD.

H2A.Zac and H4K5ac Co-occur at Promoter Regions {#sec2.4}
-----------------------------------------------

We next sought to determine whether H2A.Zac- and H4ac-marked nucleosomes co-exist in the chromatin. To address this, we determined the genomic distribution of both marks using publicly available ChIP-seq data for H2A.Zac and H4K5ac in LNCaP cells ([Table S2](#mmc1){ref-type="supplementary-material"}). The specificity of both antibodies was characterized with histone peptide arrays ([@bib48], [@bib15]) ([Figure S3](#mmc1){ref-type="supplementary-material"}A for H2A.Ztri-ac and <http://www.histoneantibodies.com/> for H4K5ac). As previously reported ([@bib49], [@bib47]), the H4K5ac antibody bound preferentially to H4 peptides that also have acetylation at other sites forming di-, tri-, and tetra-acetylation states. Thus, we considered H4K5ac ChIP-seq data as reporting on H4 N-terminal tail poly-acetylation (referred to herein as H4ac), a signature consistent with the binding activity of p300 BD ([Figure 3](#fig3){ref-type="fig"}A).

We first investigated the co-occurrence of H2A.Zac and H4ac ChIP-seq peaks genome-wide and found a significant overlap, with 51.8% of H2A.Zac peaks coinciding with H4ac ([Figure 4](#fig4){ref-type="fig"}A). To consider the predicted functional properties, we used ChromHMM ([@bib72]) to demarcate six different genomic regulatory regions based on the information from six chromatin marks ([Figure S5](#mmc1){ref-type="supplementary-material"}A and [Table S2](#mmc1){ref-type="supplementary-material"}). We found that H4ac had a similar functional distribution pattern as H2A.Zac ([@bib54]), where it was significantly enriched at promoters and enhancers and depleted at polycomb and transcribed regions ([Figure S5](#mmc1){ref-type="supplementary-material"}B). To address whether the epigenetic context impacts the coexistence of H2A.Zac and H4ac, we also performed ChromHMM analysis of the overlapping marked peaks (23,904 regions, called common peaks) and unique marked peaks for H2A.Zac or H4ac (20,876 and 15,460 regions, called H2A.Zac- or H4ac-unique peaks, respectively) ([Figure 4](#fig4){ref-type="fig"}B). We found that the common peaks were most significantly located at active promoters: 51.64% of the common peaks ([Figure 4](#fig4){ref-type="fig"}B, upper panel) and 68.74% of all active promoters ([Figure 4](#fig4){ref-type="fig"}C). In contrast, the uniquely marked regions were more prevalent at enhancers ([Figure 4](#fig4){ref-type="fig"}B, middle and bottom panels), where most of the H2A.Zac-unique peaks occurred at active enhancer regions ([Figure 4](#fig4){ref-type="fig"}B, middle panel), whereas H4ac-unique peaks were mostly enriched at poised enhancers ([Figure 4](#fig4){ref-type="fig"}B, bottom panel). However, at distal regulatory regions, we observed that both common and unique regions were present in different proportions ([Figure 4](#fig4){ref-type="fig"}D), suggesting a dynamic interplay of these two marks.Figure 4Crosstalk and Genomic Localization of H2A.Zac and H4K5ac(A) Genomic overlap of all H2A.Zac and H4ac ChIP-seq peaks. Minimum overlap equals 1bp (left panel). Observed vs expected logarithmic fold enrichment graphs using Genomic Association Test (GAT) of H2AZ.ac over H4ac and reversely (right panel). \*p value\< 0.0001.(B) GAT of H2AZ.ac and H4ac ChIP-seq peaks and ChromHMM regions in LNCaP cells. The three groups examined are H2A.Zac and H4K5ac common peaks, H2A.Zac-unique peaks, and H4K5ac-unique peaks. Pie charts representing the percentage of marked peaks falling in each ChromHMM state (left panel). Observed vs expected log-fold enrichment graphs (right panel). \*p \< 0.0001.(C and D) Heatmaps showing H2A.Zac and H4ac presence across active promoters (n = 12,770) (C) and active enhancer (n = 27,898) and poised enhancers (n = 17,354) (D). Heatmaps are divided into the same three groups than panel B and order based on H2A.Zac intensity from top to bottom. ChIP-seq signal is centered at the TSS in active promoters and at the DNAseI midpoint in enhancers. The scale bars show the color key of the ChIP-seq intensity (counts per million mapped reads, CPM). The same scale is used for each ChIP-seq across all regulatory regions.(E) Heatmaps showing H2A.Z, p300, and H3K27ac enrichment across active enhancers (left) and poised enhancers (right). Heatmaps are divided, ordered, and centered similarly to panel (D).(F) Nucleosome occupancy and methylation sequencing (NOMe-seq) plots representing the average DNA methylation (0--1) and chromatin accessibility (1 minus GpC methylation ratio) ratios across active (left hand side) and poised enhancers (right hand side) divided into the same three groups than panel (B). The average of all active and poised enhancers is also included.See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S2](#mmc1){ref-type="supplementary-material"}.

Epigenetic Characteristics of Enhancers with Differential Distribution of H2A.Zac and H4ac {#sec2.5}
------------------------------------------------------------------------------------------

In order to further define the patterns of H2A.Zac- and H4ac-marked nucleosomes at enhancers, we examined different epigenetic features at these regions, including H2A.Z, p300, and H3K27ac, DNA methylation, and chromatin accessibility ([Table S2](#mmc1){ref-type="supplementary-material"}). ChIP-seq data was split by H2A.Zac and H4ac signatures and ordered by H2A.Zac intensity at both poised and active enhancers ([Figure 4](#fig4){ref-type="fig"}E). Notably, we found that enhancers lacking H2A.Zac were not enriched for total H2A.Z, suggesting that enhancers with an H4ac-unique signature are also void of H2A.Z. Second, in agreement with a p300 BD-mediated recruitment mechanism proposed by this study and others ([@bib7], [@bib39]), p300 showed differential occupancy between groups at both active and poised enhancers; in particular, the group lacking H4ac showed less p300 occupancy. Finally, H3K27ac, a histone PTM signature characteristic of active enhancers, did not show differential distribution between the groups, although H3K27ac intensity correlated with H2A.Zac signal. These data suggest a common pattern of acetylation of H3K27ac and H2A.Zac that may be established by p300.

We next used Nucleosome Occupancy and Methylation sequencing (NOMe-seq) data to study DNA methylation and chromatin accessibility at these enhancer sites ([@bib30]). We found that H2A.Zac-unique enhancers had less DNA methylation and were more accessible than the average of all active and poised enhancers. In contrast, H4ac-unique active and poised enhancers had more methylation and were less accessible ([Figure 4](#fig4){ref-type="fig"}F). Enhancers carrying both H2A.Zac and H4ac had similar levels of DNA methylation and accessibility as the average enhancers. In summary, we found that enhancers with differential H2A.Zac and H4ac signatures are associated with distinct epigenetic features ([Figure 6](#fig6){ref-type="fig"}B).

Acetylation Dynamics between H2A.Z and H4 at Enhancers Is Associated with Transcription Elongation {#sec2.6}
--------------------------------------------------------------------------------------------------

Chromatin accessibility and DNA methylation are indicative of enhancer activity ([@bib54]). To characterize the functional status of each enhancer H4/H2A.Z acetylation signature, we examined RNA polymerase II (RNApolII) recruitment and enhancer RNA (eRNA) production ([@bib32]) as additional markers of enhancer function ([Table S2](#mmc1){ref-type="supplementary-material"}). [Figure 5](#fig5){ref-type="fig"}A shows RNApolII ChIP-seq signal and Global Run-on sequencing (GRO-seq) data across active and poised enhancers. eRNA production is measured as the bidirectional RNA expression detected by GRO-seq around the DNAseI midpoint. Despite no major differences between H2A.Zac/H4ac signatures in eRNA production and the presence of RNAPolII flanking DNAseI sites, we did reveal evidence of differential transcription across the entire 4kb region plotted ([Figure 5](#fig5){ref-type="fig"}A). H2A.Zac-unique enhancers had less regional transcriptional activity than the other two groups (common and H4ac-unique) in both active and poised enhancers.Figure 5Transcription Elongation Influences H2A.Zac and H4K5ac Landscape at Enhancers(A) Heatmaps showing phosphoserine 5 RNA polymerase II (RNAPolII) ChIP-seq and global run-on sequencing (GRO-seq) signal across active and poised enhancers. The three groups examined are H2A.Zac and H4ac overlapping peaks (Common, yellow), H2A.Zac-unique peaks (H2A.Zac-unique, light blue), and H4ac-unique peaks (H4ac-unique, dark blue) at active (left) and poised (right) enhancers that are at least 2kb away from any TSS. Heatmaps are ordered based on H2A.Zac intensity from top to bottom. The scale bars show the color key of the ChIP-seq and GRO-seq intensities (counts per million mapped reads, CPM).(B) Bar plots showing the proportion of intragenic (black) and intergenic (gray) active and poised enhancers in each H2A.Zac/H4ac group. The red dashed line marks the proportion of intergenic and intragenic enhancers found in all active and poised enhancers.(C) Box plots comparing gene expression as logarithmic transcripts per million (logTPM) measured by RNA-seq of the genes contained on each intragenic active (left) or poised enhancers for each H2A.Zac/H4ac group and all the genes containing at least one enhancer (gray box plot).(D) Bidirectional enhancer RNAs (eRNAs) profile plots (plus, red, and negative, blue-strands) of GROseq data around intragenic and intergenic active enhancers (top) and poised enhancers (bottom) of the H2A.Zac/H4ac groups. The plots show one representative replicate out of four. Profiles are centered at the DNAse I midpoint.See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

To confirm that the observed transcription signal at expanded enhancers was due to transcription elongation, we grouped the enhancers according to their location inside or outside genes and compared their proportion with the rest of the enhancers ([Figure 5](#fig5){ref-type="fig"}B). A higher proportion of H4ac-unique enhancers were located at intragenic regions. H2A.Zac-unique active enhancers did not show differential localisation, whereas H2A.Zac-unique poised enhancers showed a higher presence at intergenic regions ([Figure 5](#fig5){ref-type="fig"}B). Common enhancers had similar inter/intragenic distribution to all detectable active and poised enhancers. We also found that genes with H2A.Zac-unique enhancers had significantly lower transcription compared with all genes containing either active or poised enhancers, whereas H4ac-unique enhancers were mostly present at highly expressed genes ([Figure 5](#fig5){ref-type="fig"}C). Moreover, the nascent RNA profiles measured by GROseq at intragenic enhancers validated the gene expression pattern ([Figures 5](#fig5){ref-type="fig"}D and [S5](#mmc1){ref-type="supplementary-material"}C).

Taken together, these results demonstrate a particular H2A.Zac and H4ac pattern, or enhancer code, that correlates with their genomic localization (inter or intragenic), regional transcriptional activity, chromatin features (p300, chromatin accessibility), and DNA methylation ([Figure 6](#fig6){ref-type="fig"}B).Figure 6Model Figure of H2A.Z Acetylation Writing Mechanism(A) Proposed models for Tip60- and p300-mediated acetylation of H2A.Z. (1) Sequential cascade: Tip60 acetylates H4, which drives recruitment of p300 and acetylation of H2A.Z. (2) Independent mechanisms: Tip60 directly targets acetylation of H2A.Z potentially during histone exchange and p300 acetylates H2A.Z at the chromatin to maintain nucleosomal acetylation.(B) The combinatorial subgroups of H2A.Zac and H4ac at enhancers are snapshot of a dynamic mechanism for enhancer activation through three states: poised, poised-active, and active.

Discussion {#sec3}
==========

A key step to understanding histone PTM function is the characterization of the enzymes and effector proteins that write, erase, and read these marks. Although much progress has been made identifying the core histone PTM modifiers ([@bib57]), the specific enzymes that target histone variants PTMs have not been well studied. In particular, the KATs responsible for acetylation of H2A.Z in mammals are still unresolved. Here, we report that in addition to Tip60, p300 is able to acetylate the histone variant H2A.Z and that p300-dependent H2A.Z acetylation is enhanced through BD recognition of H4ac.

Unlike Tip60, p300 has not been described to interact with H2A.Z ([@bib4], [@bib37], [@bib44], [@bib55]), as it potentially follows a hit-and-run kinetic mechanism ([@bib38]). Tip60, however, has been described as the KAT candidate responsible for acetylation of H2A.Z ([@bib9], [@bib19], [@bib52]). Tip60 is part of a larger complex, involved in H2A.Z histone exchange ([@bib1], [@bib3], [@bib31], [@bib33]), which makes it difficult to assess whether Tip60 alone is able to acetylate H2A.Z. In fact, our *in vitro* results show that Tip60 acetylates peptide and nucleosomal H4 but does not efficiently acetylate H2A.Z. However, we and others ([@bib11], [@bib36]) found that genetic inhibition of Tip60 decreases H2A.Zac levels, suggesting that Tip60, in its cellular context, facilitates H2A.Z acetylation. Of note, complete knockout of Tip60 does not abolish H2A.Zac ([@bib36]), and other reports found that acetylation of H2A.Z was independent of Tip60 at some locus-specific promoter ([@bib2], [@bib51]), supporting our finding that p300/CBP is also required for the acetylation of H2A.Z. Based on our new data, we propose a model whereby acetylation of H2A.Z is the result of a sequential cascade initiated by Tip60-mediated acetylation of H4, leading to the recruitment of p300 via its BD to acetylate H2A.Z. Alternatively, Tip60 and p300/CBP may acetylate H2A.Z directly through independent pathways ([Figure 6](#fig6){ref-type="fig"}A).

We provide biochemical evidence that the presence of acetylated H4 in the nucleosome can have impact on p300-mediated acetylation of H2A.Z, suggesting that these two marks are co-localized. It was previously shown by immunoprecipitation that H2A.Z nucleosomes are enriched for H4ac ([@bib17], [@bib41]). Based on our analysis of ChIP-seq data, we found that H2A.Zac and H4ac co-occurred predominantly at promoters and enhancers. However, at a third of all enhancers, these marks did not co-occur. After dissecting the epigenetic features of each sub-group of enhancers, we propose a dynamic mechanism for enhancer activation through three states of activity ([Figure 6](#fig6){ref-type="fig"}B): poised, poised-active, and active. Each state has a preferential H4ac/H2A.Zac combination that would initiate from H4ac-marked nucleosomes at poised enhancers that enables the recruitment of p300 through its BD. This may trigger H2A.Z acetylation through p300 in a poised/active state and deacetylation of H4 in a fully enhancer-activated state.

Additionally, we also find different transcriptional features of each state. H2A.Zac-unique enhancers are enriched at intergenic regions or within lowly expressed genes; conversely, H4ac-unique enhancers are present in intragenic regions and are associated with highly transcribed genes, whereas common enhancers are characterized by an intermediate state regarding transcription elongation. The lack of H2A.Zac at intragenic enhancers of highly expressed genes could be due to the previously reported active removal of H2A.Z at gene bodies during transcription elongation ([@bib22], [@bib34]). It is therefore interesting to note that H2A.Zac-marked active enhancers are not present within the gene they activate, as transcription elongation of the gene would remove H2A.Z from the enhancer, suggesting that H2A.Zac enhancers are likely acting as trans-regulatory elements. In this regard, a recent study showed that functionally active intragenic enhancers can attenuate transcription of the host gene ([@bib5]), supporting our observation.

In contrast, the lack of H4ac at H2A.Zac-unique enhancers is less clear. Genome-wide mapping of KATs and lysine deacetylases (KDACs) have shown that both enzyme families are targeted to active genes and correlate with transcription levels ([@bib58]), which suggests a high turnover rate of histone acetylation at highly transcribed genes compared with lowly transcribed genes or intergenic regions. Weinert et al. data reported a higher deacetylation rate of H4 compared with H2A.Z ([@bib59]). We, therefore, propose that these different kinetics could partially explain the lack of H4ac at these H2A.Zac regions. However, we cannot rule out that p300 and Tip60 are able to acetylate H2A.Z without the presence of H4ac at these particular sites.

Collectively, we demonstrate that p300/CBP, complementary to Tip60, are essential KATs for the acetylation of H2A.Z, answering the long-standing question of what enzymes are responsible for this important modification. We reveal a mechanism of histone PTM crosstalk and define an enhancer code based on the patterning of H4ac and H2A.Zac. Both p300 and H2A.Z have been implicated in many human cancers (reviewed in [@bib28], [@bib56]); therefore, this study provides p300 as an additional target for H2A.Zac-based chromatin therapy in cancer.

Limitations of the Study {#sec3.1}
------------------------

In this study we demonstrate that p300-BD interaction with H4ac enhances H2A.Z acetylation using an inhibitor of p300 BD. However, we were not able to directly compare p300-mediated acetylation in a nucleosomal context with pre-installed H4ac/H2A.Z nucleosomes due to the technical difficulty in generating recombinant H4ac/H2A.Z combinatorial nucleosomes *in vitro*. Additionally, we found that H2A.Zac levels are reduced after inhibition of both Tip60 and p300, but we were unable in this study to determine if the mechanism that results in H2A.Zac involves a sequential cascade through H4ac or occurs through independent pathways. Future studies will focus on resolving the interplay and order of events that are associated with Tip60 and p300 in driving the acetylation of H2A.Z.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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